Bernhard Scheiner

#xliver #PortalHypertension #ClinicalTrials FANs! 👋 Introducing the next work-package focusing on patients with porto-sinusoidal vascular disorder. #PSVD 🌐More info in the video below 🔽

#twitterliver #PortalHypertension WP1 focuses on the classical & alternative renin-angiotensin system as a disease-driving mechanism in patients with compensated advanced chronic liver disease & investigates potentially beneficial effects of telmisartan in this patient group.⬇️⬇️

Direct link to the registration: ilca-online.org/education/ilca…

What’s the best approach to treat advanced #HCC and special subgroups? 🤔 Looking forward to the discussion at the next ILCA webinar tomorrow @ArndtVogel & @SaborowskiAnna @ILCAnews 🗓️12 December 2024 🕒3:00-4:00 CET 🆓Free Webinar Register here: ilca-online.org/education/ilca…

🔥New research--> focusing on longitudinal body composition trajectories in #HCC patients Falling trajectories with refractory #cachexia/#sarcopenia are linked to 👉 poorest survival rates 👉poorest response to #immunotherapies. Special thanks to @DJPinato @BernharScheiner @FanpuJi #MedTwitter #Oncology shorturl.at/DoMLo

Join us at the EASL #LiverCancerSummit 2025, on 20-22 February in Paris & online! 🌍 🦀Dive into cutting-edge research, expert-led sessions, and networking with global specialists in liver cancer care. Don’t miss this chance to explore breakthroughs in hepatocellular and cholangiocellular carcinoma. 🏆Gain 12.5 CME Credits! Learn more & register! easl.eu/event/liver-ca… @Caldera60373705 @rirmacias @AleksanderKrag @DebbieShawcros1 @NaultJc

🙏Thank you very much for the great collaboration: @ArndtVogel @SaborowskiAnna @DJPinato @A_DAlessioMD @LorenzaRimassa @JDekervel @MarkusPeck1 @JohannvonFelden @balcar_lorenz @FulgenziClaudia and many more Editorial by: @MarcoSanduzzi @cabibbo78

Outcome of pts with HCC and CR to ICI-therapy @HEP_Journal doi.org/10.1097/HEP.00… - full text available 😀 🧑‍🤝‍🧑~4% of ICI-patients 🎯Excellent long-term outcomes ‼️Treatment >6 months after CR important 👏Excellent editorial worth a read: doi.org/10.1097/HEP.00… @PinterMatthias

Outcome of pts with HCC who achieved CR to ICI-based systemic therapy @HEP_Journal doi.org/10.1097/HEP.00… 🔎🌎RWD, 3933 pts 👉1- & 3-year RFS: 78% & 55% 👉1- & 3-year OS: 98% & 86% 😅Just great to report RFS in advanced HCC w/ ICI❗️ 🧐only 4%, but we are getting there... @myESMO @EASLedu @ILCAnews #liverwitter

#LiverX Metabolomic profiles differentiate between porto-sinusoidal vascular disorder (#PSVD) & cirrhosis (#ACLD) 🟢 taurocholic acid (AUROC 0.899) 📕@JHEP_Reports by @GeorgSemmler @xander_petrenko @BernharScheiner @jcgarciapagan 🔗sciencedirect.com/science/articl…

⁉️ What to do after response achievement with #immunotherapy in #HCC? 🧐 No definitive answer. Here we share some thoughts 💭 with @cabibbo78 🐚 ⚠️ The study of @BernharScheiner out in @HEP_Journal soon!

Very proud and thankful to see this study on metabolomic profiles in cirrhosis and PSVD finally published. I am more than grateful for the team working on this project - especially @GeorgSemmler and @xander_petrenko as well as our collaboration partners @jcgarciapagan! 😀

Our paper on immunotherapy in CPB HCC is out on @JAMAOnc! Thanks to all the co-authors for their precious support! A special acknowledgment is for @ACortelliniMD for his invaluable statistical support, and to the rest of my amazing team @DJPinato @A_DAlessioMD @CiroCelsa

Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction - another piece of the puzzle by @FulgenziClaudia @ImperialSandC @UniAvogadro jamanetwork.com/journals/jamao…

@AndrewMMoon @EASLnews @ma5RN @NDP1001 Thank you very much! Was a pleasure to meet you!

Great study by Bernhard Scheiner on outcomes of patients with HCC who achieved complete response on immunotherapy-based regimens Improved outcomes among patients who continued therapy beyond 6 mos after CR, suggesting we should continue therapy if well-tolerated #EASLCongress

🔥news from #EASL2024 Outcome of pts with HCC who achieved a complete response to ICI-based therapy 👉🗺️RWD, 174/3933 pts 👉mRFS 30 mo, 3yr OS 87% 😅Great to report recurrence free survival (!) after systemic therapy in advanced HCC @myESMO @EASLedu @ILCAnews #livertwitter

"Von Willebrand factor for outcome prediction within different clinical stages of advanced chronic liver disease" now free to read at bit.ly/49T2dFj #livertwitter

Immunotherapy is truly changing all stages of hepatocellular carcinoma⁦. Honoured to have been tasked to make sense of this change with ⁦@A_DAlessioMD⁩ ⁦@FulgenziClaudia⁩ for ⁦@NatureMedicine⁩ ⁦@ImperialSandC⁩ ⁦@UniAvogadro⁩ nature.com/articles/s4159…

🆕 A meta-analysis reveals intriguing sex-related differences in immunotherapy for hepatocellular carcinoma: ✳️ 5 Phase III trials included, females showed smaller overall survival ✅ No significant sex-based differences in safety profiles 🌏 While real-world data coming from an international cohort of 840 patients treated with atezo + beva did not find any significant difference in survival between sexes 🤔 More research into gender-specific responses is needed 🔓 bit.ly/3NuWY5o in @JHEP_Reports #livertwitter #HCC